Colorectal Cancer
Studies of asymptomatic and symptomatic patients have demonstrated lower ctDNA detection in asymptomatic patients.
The RAMTAS trial explored ramucirumab plus TAS102, benefiting select chemotherapy-refractory mCRC patients.
Combining encorafenib and cetuximab with FOLFIRI chemotherapy showed strong antitumor activity in BRAF V600E-mutant mCRC.
Amivantamab plus chemo shows encouraging and durable antitumor activity for anti-EGFR-naïve RAS/RAF wild-type mCRC.
Neoadjuvant nivolumab plus relatlimab led to a pathologic response rate of 96%.
The CodeBreaK 101 study assessed the safety and efficacy of soto, pani, and FOLFIRI for KRAS G12C-mutated mCRC.
Cetuximab rechallenge guided by liquid biopsy improved response and disease control rates in RAS wild-type mCRC.
1L zanidatamab plus chemo with or without bevacizumab demonstrated antitumor activity and manageable safety in mCRC.
The latest data from the RECAST trial shed light on FOLFIRI plus RAM for patients with metastatic CRC.
Dr. Grady opines on whether colonoscopy, stool-based, or blood-based tests will be integrated into CRC screening guidelines.
Dr. Grady discusses ECLIPSE for colorectal cancer screening and the findings that led to approval of the Shield test.
Dr. Lieu breaks down his top uses of AI in GI oncology today, as well as their projected applicability in the near future.
Advertisement
Roundtable Discussions
Advertisement
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.